Name: Pristinamycin
Price: 504.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Pristinamycin IIA binds to the bacterial 50S subunit of 70S bacterial ribosomes, triggering a conformational change and enhancing the afficinity for the second component, Pristinamycin IA. The result is irreversible binding, arrested protein synthesis, and a bactericidal effect. The biosynthetic gene cluster is the largest nown antibiotic supercluster with the genes scattered across the sequence region.
- Properties
  - CAS Number
    
    270076-60-3
    
    Molecular Formula
    
    C45H54N8O10 (PI)/C28H35N3O7 (PII)
    
    Molecular Weight
    
    866.96 (PI)/525.59 (PII)
    
    Appearance
    
    white or almost white powder
    
    Solubility
    
    DMSO (very soluble). Soluble in methanol, ethanol, chloroform. (ref: PubChem)
    
    Other Properties
    
    Source: Streptomyces pristinaespiralis
    Purity Level: ≥95% (by HPLC)
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: Bactericidal activity against Gram-positive bacteria. Effective against methicillin-resistant S. aureus (MRSA). Effective against erythromycin-resisant Staphylococci and Streptococci.
    
    Microbiology Applications: Eleven strains of Streptococcus pneumoniae were exposed to subinhibitory concentrations of Pristinamycin (or others antibiotics including Azithromycin, Clarithromycin, Clindamycin, Erythromycin, Roxithromycin, Telithromycin) to determine if resistance developed. Daily passaging in subinhibitory concentrations was done for a maximum of 50 days.Altogether, there were a total of 54 mutants with elevated MICs to at at least one of these antibiotics. Of these mutants, 20 had Pristinamycin resistance (Davies et al, 2000).
    
    Eukaryotic Cell Culture Applications: The interaction of Pristinamycin IA with the multidrug transporter P-glycoprotein was investigated in the human intestinal epithelial cell line Caco-2. It inhibited the efflux of the P-glycoprotein substrate [3H]vinblastine, thus increasing the cellular accumulation. Thus, the Pristinamycin IA is a substrate for the P-glycoprotein (Phung-Ba et al, 1995).